Amended And Restated License Agreement Sample Contracts

Predictive Technology Group, Inc,. – Second Amended and Restated License Agreement (December 6th, 2018)

THIS SECOND AMENDED AND RESTATED LICENSE AGREEMENT (the Agreement) is effective as of the 31st day of March, 2018 (the Effective Date) is by and between Juneau Biosciences, LLC, a Utah Limited Liability Corporation with its offices at 2749 East Parleys Way, Suite 210, Salt Lake City, UT 84109 (Juneau), and Predictive Technology Group, Inc., a Nevada corporation with its offices at 2735 East Parleys Way, Suite 205, Salt Lake City, Utah 84109 (Predictive).

Amendment No. 1 to Amended and Restated License Agreement (November 7th, 2018)
Ocular Therapeutix, Inc – Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Double Asterisks Denote Omissions. SECOND AMENDED AND RESTATED LICENSE AGREEMENT (September 19th, 2018)

This Second Amended and Restated License Agreement (Agreement) dated as of September 13, 2018 (the Effective Date), is by and between Incept LLC (Incept), a Delaware Limited Liability Company, with offices located at 1359 Dell Avenue, Campbell, CA 95008 and Ocular Therapeutix, Inc. (Ocular), a Delaware corporation with offices located at 15 Crosby Dr, Bedford, MA 01730 (each of Incept and Ocular a Party and, collectively, the Parties to this Agreement).

Eastside Distilling, Inc. – Amended and Restated License Agreement (August 13th, 2018)

This AMENDED AND RESTATED LICENSE AGREEMENT (this "Agreement"), dated as of this 31st day of May, 2018 ("Effective Date"), is entered into by and between RICH MARKS, LLC, a Delaware limited liability company "Licensor"), Redneck Riviera Whiskey Co., LLC, a Tennessee limited liability company ("Licensee"), John D. RICH TISA Trust U/A/D MARCH 27, 2018, DWIGHT P. WILeS, TRUSTEE ("Trust"), and EASTSIDE DISTILLING, INC., a corporation organized under the laws of the State of Nevada ("Former Licensee").

Transdel Pharmaceuticals – Amended and Restated License Agreement (August 6th, 2018)

THIS AMENDED AND RESTATED LICENSE AGREEMENT (the "Agreement") dated as of the last date provided for on the signature page hereto (the "Restatement Date"), is entered into between Richard L. Lindstrom, M.D., an individual ("Lindstrom"), with a principal place of business at Minnesota 55391 and Imprimis Pharmaceuticals, Inc., a Delaware corporation ("Imprimis"), with a principal place of business at 12264 El Camino Real, Suite 350, San Diego, California 92130.

Gemphire Therapeutics Inc. – Amended and Restated License Agreement (August 6th, 2018)

THIS AMENDED AND RESTATED LICENSE AGREEMENT (this "Agreement") is made effective as of the 2nd day of August, 2018 (the "Effective Date"), by and between Gemphire Therapeutics Inc., a Delaware corporation with offices at 17199 N. Laurel Park Dr., Suite 401, Livonia, MI 48152 ("LICENSEE"), and Pfizer Inc., a corporation organized and existing under the laws of Delaware with offices at 235 East 42nd Street, New York, NY 10017 ("PFIZER"). LICENSEE and PFIZER may, from time-to-time, be individually referred to as a "Party" and collectively referred to as the "Parties."

Liquidia Technologies Inc – Amended and Restated License Agreement (June 28th, 2018)

This LICENSE AGREEMENT is entered into as of December 15, 2008 and is hereby made effective as of December 15, 2008 (the EFFECTIVE DATE) by and between The University of North Carolina at Chapel Hill having an address at Campus Box 4105, 308 Bynum Hall, Chapel Hill, North Carolina, 27599-4105 (hereinafter referred to as UNIVERSITY) and Liquidia Technologies, Inc., a corporation organized and existing under the laws of the State of Delaware having its principal office/place of business at 419 Davis Drive, Suite 100, Durham, NC 27713 (hereinafter referred to as LICENSEE).

Cempra Inc. – Amended and Restated License Agreement (June 8th, 2018)

This Amended and Restated License Agreement (this Agreement) is made this first of May, 2017 (the Amendment Effective Date), by and between Wakunaga Pharmaceutical Co., Ltd. (hereinafter referred to as WAKUNAGA), a corporation duly organized and existing under the laws of Japan and having its principal office at 5-36, Miyahara 4-chome, Yodogawa-Ku, Osaka, Japan and Melinta Therapeutics, Inc. (formerly known as Rib-X Pharmaceuticals, Inc. and hereinafter referred to as MELINTA), a corporation duly organized and existing under the laws of Delaware, U.S.A. and having its principal office at 300 George Street, Suite 301, New Haven, Conn., 06511 U.S.A., and amends and restates in its entirety the License Agreement dated May 12, 2006 by and between WAKUNAGA and MELINTA, as previously amended (the 2006 Agreement).

2-8 Tamagawa-Dai Setagaya-Ku Tokyo, 158-0096 JAPAN Re: Novated, Amended and Restated License Agreement Gentlemen: (May 15th, 2018)

I am writing on behalf of Argos Therapeutics, Inc. ("Argos") with respect to the Novated, Amended and Restated License Agreement dated as of October 1, 2014, as amended (the "License Agreement"), by and among Argos, Medinet Co., Ltd. ("Medinet"), and MEDcell Co., Ltd. ("MEDcell" and together with Medinet, the "Medinet Parties").

Liquidia Technologies Inc – Amended and Restated License Agreement (May 10th, 2018)

This LICENSE AGREEMENT is entered into as of December 15, 2008 and is hereby made effective as of December 15, 2008 (the EFFECTIVE DATE) by and between The University of North Carolina at Chapel Hill having an address at Campus Box 4105, 308 Bynum Hall, Chapel Hill, North Carolina, 27599-4105 (hereinafter referred to as UNIVERSITY) and Liquidia Technologies, Inc., a corporation organized and existing under the laws of the State of Delaware having its principal office/place of business at 419 Davis Drive, Suite 100, Durham, NC 27713 (hereinafter referred to as LICENSEE).

Liquidia Technologies Inc – Amended and Restated License Agreement (April 4th, 2018)

This LICENSE AGREEMENT is entered into as of December 15, 2008 and is hereby made effective as of December 15, 2008 (the EFFECTIVE DATE) by and between The University of North Carolina at Chapel Hill having an address at Campus Box 4105, 308 Bynum Hall, Chapel Hill, North Carolina, 27599-4105 (hereinafter referred to as UNIVERSITY) and Liquidia Technologies, Inc., a corporation organized and existing under the laws of the State of Delaware having its principal office/place of business at 419 Davis Drive, Suite 100, Durham, NC 27713 (hereinafter referred to as LICENSEE).

First Amendment to Second Amended and Restated License Agreement (March 15th, 2018)

This First Amendment (this "Amendment") is made on November __, 2017 as an amendment to the Second Amended and Restated License Agreement of June 15, 2017 (the "Agreement"), by and between HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. ("Hadasit") and CELL CURE NEUROSCIENCES LTD. (the "Company") (each a "Party" and jointly the "Parties"), effective as of the same date as the Agreement.

Cempra Inc. – Amended and Restated License Agreement (March 14th, 2018)

This Amended and Restated License Agreement (this Agreement) is made this first of May, 2017 (the Amendment Effective Date), by and between Wakunaga Pharmaceutical Co., Ltd. (hereinafter referred to as WAKUNAGA), a corporation duly organized and existing under the laws of Japan and having its principal office at 5-36, Miyahara 4-chome, Yodogawa-Ku, Osaka, Japan and Melinta Therapeutics, Inc. (formerly known as Rib-X Pharmaceuticals, Inc. and hereinafter referred to as MELINTA), a corporation duly organized and existing under the laws of Delaware, U.S.A. and having its principal office at 300 George Street, Suite 301, New Haven, Conn., 06511 U.S.A., and amends and restates in its entirety the License Agreement dated May 12, 2006 by and between WAKUNAGA and MELINTA, as previously amended (the 2006 Agreement).

Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Double Asterisks Denote Omissions. THIRD AMENDED AND RESTATED LICENSE AGREEMENT (March 7th, 2018)

THIS THIRD AMENDED AND RESTATED LICENSE AGREEMENT (this AGREEMENT), dated as of March 14, 2013 (the THIRD AMENDMENT EFFECTIVE DATE), by and between YALE UNIVERSITY, a corporation organized and existing under and by virtue of a charter granted by the general assembly of the Colony and State of Connecticut and located in New Haven, Connecticut (YALE), and KOLLTAN PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware, and with principal offices located at 300 George Street, New Haven, CT 06511 (LICENSEE) is effective as of the THIRD AMENDMENT EFFECTIVE DATE.

Second Amendment to Mayo Foundation for Medical Education and Research Amended and Restated License Agreement (February 22nd, 2018)

This Second Amendment (this "Amendment") to the Mayo Foundation for Medical Education and Research Amended and Restated License Agreement dated effective January 31, 2015 ("Restated Agreement"), is entered into between MAYO Foundation for Medical Education and Research, ("MAYO"), Exact Sciences Corporation ("EXACT"), and Exact Sciences Development Company, LLC ("ESDC"), a wholly-owned subsidiary of EXACT. This Amendment is executed on the dates indicated below, but shall be deemed effective as of October 1, 2017 ("Amendment Effective Date").

CBOE Holdings – Amendment No. 2 to Amended and Restated License Agreement Dated as of September 29, 2006 by and Between DJI Opco, LLC ("DJI Opco") and CBOE as Previously Amended (The "2006 Agreement") (December 22nd, 2017)

This Amendment (this "Amendment") is made as of December 21, 2017 (the "Amendment Effective Date") and, with respect to the 1994 Agreement, is by and between S&P and CBOE, and, with respect to the 2006 Agreement, is by and between DJI Opco and CBOE (DJI Opco being a wholly owned subsidiary of S&P, and the successor by assignment to Dow Jones & Company, Inc., the original party with CBOE to the 2006 Agreement).

Monopar Therapeutics – Amended and Restated License Agreement (December 20th, 2017)

THIS AMENDED AND RESTATED LICENSE AGREEMENT (this "Agreement"), effective as of September 24, 2014 (the "Effective Date"), is entered into between Tactic Pharma, LLC, a limited liability company ("TACTIC"), having offices at 1062 Princeton Avenue, Highland Park, IL 60035 and XOMA (US) LLC, a Delaware limited liability company ("XOMA"), having offices at 2910 Seventh Street, Berkeley, California 94710. Each of XOMA and TACTIC are sometimes referred to herein separately as a "Party" and together as "Parties."

Amended and Restated License Agreement (December 19th, 2017)

This AMENDED AND RESTATED LICENSE AGREEMENT ("Agreement") is entered into as of the 16th day of May 2017 ("the Effective Date"), by and between Dai Nippon Printing Co., Ltd., a corporation organized under the laws of Japan, with its principal place of business at 1-1-1, Ichigaya-Kagacho, Shinjuku-ku, Tokyo 162-8001, Japan ("DNP") and Photronics DNP Mask Corporation (formerly known as Photronics Semiconductor Mask Coroporation), a corporation organized under the laws of the Republic of China (hereinafter "ROC" or "Taiwan") , with its registered office at 1F, No. 2, Lising Road, Hsinchu City, Hsinchu Science Park, Taiwan, R.O.C ("Company"). Each of DNP and the Company is hereafter referred to as a "Party" and collectively the "Parties".

Cue Biopharma, Inc. – Confidential Portions of This Agreement Have Been Omitted and Filed Separately With the Commission. Confidential Treatment Has Been Requested for Such Portions. Asterisks Denote Omissions. Amended and Restated License Agreement (December 13th, 2017)

This Amended and Restated License Agreement ("Agreement") is entered into as of July 31, 2017 ("Restated Agreement Effective Date"), by and between Albert Einstein College of Medicine, Inc., a corporation organized and existing under the laws of the State of New York, having an office and place of business at 1300 Morris Park Avenue, Bronx, New York 10461 as successor-in-interest to Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva University, ("Licensor") and Cue Biopharma Inc., formerly known as Imagen Biopharma, Inc., a corporation organized and existing under the laws of the State of Delaware, having an office and place of business at do MDB Capital Group LLC, 401 Wilshire Blvd, Suite 1020, Santa Monica, California 90401 ("Licensee").

Cue Biopharma, Inc. – Confidential Portions of This Agreement Have Been Omitted and Filed Separately With the Commission. Confidential Treatment Has Been Requested for Such Portions. Asterisks Denote Omissions. Amended and Restated License Agreement (December 11th, 2017)

This Amended and Restated License Agreement ("Agreement") is entered into as of July 31, 2017 ("Restated Agreement Effective Date"), by and between Albert Einstein College of Medicine, Inc., a corporation organized and existing under the laws of the State of New York, having an office and place of business at 1300 Morris Park Avenue, Bronx, New York 10461 as successor-in-interest to Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva University, ("Licensor") and Cue Biopharma Inc., formerly known as Imagen Biopharma, Inc., a corporation organized and existing under the laws of the State of Delaware, having an office and place of business at do MDB Capital Group LLC, 401 Wilshire Blvd, Suite 1020, Santa Monica, California 90401 ("Licensee").

Neothetics, Inc. – Confidential Treatment Requested Amended and Restated License Agreement (November 15th, 2017)
Monopar Therapeutics – Amended and Restated License Agreement (November 9th, 2017)

THIS AMENDED AND RESTATED LICENSE AGREEMENT (this "Agreement"), effective as of September 24, 2014 (the "Effective Date"), is entered into between Tactic Pharma, LLC, a limited liability company ("TACTIC"), having offices at 1062 Princeton Avenue, Highland Park, IL 60035 and XOMA (US) LLC, a Delaware limited liability company ("XOMA"), having offices at 2910 Seventh Street, Berkeley, California 94710. Each of XOMA and TACTIC are sometimes referred to herein separately as a "Party" and together as "Parties."

Quanterix Corp – Amended and Restated License Agreement (November 9th, 2017)

THIS AMENDED AND RESTATED LICENSE AGREEMENT (hereinafter the Agreement) is made this 22nd day of December, 2016 (the Effective Date):

Bluebird Bio Inc. – Amended and Restated License Agreement by and Between Bluebird Bio, Inc. And Celgene Corporation and Celgene European Investment Company LLC (November 1st, 2017)
Spero Therapeutics, Inc. – Amended and Restated License Agreement (October 23rd, 2017)

This Amended and Restated License Agreement (this Agreement), dated as of June 28, 2017 (the Effective Date), is made by and between Northern Antibiotics Oy (Ltd.), a corporation organized under the laws of Finland (Northern), and Spero Potentiator, Inc., a Delaware corporation (Spero). Northern and Spero are sometimes hereinafter referred to each as a Party and collectively as the Parties.

Spero Therapeutics, Inc. – Amended and Restated License Agreement (October 6th, 2017)

This Amended and Restated License Agreement (this Agreement), dated as of June 28, 2017 (the Effective Date), is made by and between Northern Antibiotics Oy (Ltd.), a corporation organized under the laws of Finland (Northern), and Spero Potentiator, Inc., a Delaware corporation (Spero). Northern and Spero are sometimes hereinafter referred to each as a Party and collectively as the Parties.

Amended and Restated License Agreement Between Horizon Orphan Llc and the Regents of the University of California for Case Nos. Sd2006-092, Sd2017-110, Sd2017-113 and Sd2017-236 (September 28th, 2017)

This agreement (Agreement) is made by and between Horizon Orphan LLC, as successor in interest to Raptor Pharmaceuticals, Inc. (f/k/a Encode Pharmaceuticals, Inc.), a Delaware limited liability company having an address at 150 South Saunders Road, Lake Forest, Illinois 60045 (LICENSEE) and The Regents of the University of California, a California corporation having its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607-5200 (UNIVERSITY), represented by its San Diego campus having an address at University of California, San Diego, Office of Innovation and Commercialization, Mail Code 0910, 9500 Gilman Drive, La Jolla, California 92093-0910 (UCSD). This Agreement is being entered into as of the date of last signature below (Execution Date) and is deemed effective as of October 31, 2007 (Effective Date).

Relmada Therapeutics, Inc. – Amended and Restated License Agreement (September 28th, 2017)

This Agreement amends and restates in its entirety that certain Office Space License Agreement, dated as of March 10, 2016 and effective as of January 1, 2016, between Relmada and Actinium (the "Original Agreement") for office space within the Premises. This Agreement is intended to and does completely amend and restate the Original Agreement.

Spero Therapeutics, Inc. – Amended and Restated License Agreement (September 22nd, 2017)

This Amended and Restated License Agreement (this Agreement), dated as of June 28, 2017 (the Effective Date), is made by and between Northern Antibiotics Oy (Ltd.), a corporation organized under the laws of Finland (Northern), and Spero Potentiator, Inc., a Delaware corporation (Spero). Northern and Spero are sometimes hereinafter referred to each as a Party and collectively as the Parties.

Cue Biopharma, Inc. – Confidential Portions of This Agreement Have Been Omitted and Filed Separately With the Commission. Confidential Treatment Has Been Requested for Such Portions. Asterisks Denote Omissions. Amended and Restated License Agreement (September 21st, 2017)

This Amended and Restated License Agreement ("Agreement") is entered into as of July 31, 2017 ("Restated Agreement Effective Date"), by and between Albert Einstein College of Medicine, Inc., a corporation organized and existing under the laws of the State of New York, having an office and place of business at 1300 Morris Park Avenue, Bronx, New York 10461 as successor-in-interest to Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva University, ("Licensor") and Cue Biopharma Inc., formerly known as Imagen Biopharma, Inc., a corporation organized and existing under the laws of the State of Delaware, having an office and place of business at do MDB Capital Group LLC, 401 Wilshire Blvd, Suite 1020, Santa Monica, California 90401 ("Licensee").

Quanterix Corp – Amended and Restated License Agreement (August 17th, 2017)

THIS AMENDED AND RESTATED LICENSE AGREEMENT (hereinafter the Agreement) is made this 22nd day of December, 2016 (the Effective Date):

Audentes Therapeutics, Inc. – Amended and Restated License Agreement (August 10th, 2017)

This Amended and Restated License Agreement ("Agreement") is effective as of September 26, 2014 (the "Effective Date") by and between Istituti Clinici Scientifici Maugeri S.p.A. SB (assignee of Fondazione Salvatore Maugeri, "FSM"), an organization established under the laws of Italy ("Maugeri"), and Audentes Therapeutics, Inc., a Delaware corporation ("Audentes"), and amends and restates in its entirety that certain License Agreement dated as of the Effective Date by and between Cardiogen Sciences, Inc. ("Cardiogen") and FSM (the "Original Agreement"). Each of Maugeri and Audentes are referred to herein as "Party" and together as the "Parties."

Amended and Restated License Agreement Between Horizon Orphan Llc and the Regents of the University of California for Case Nos. Sd2006-092, Sd2017-110, Sd2017-113 and Sd2017-236 (August 7th, 2017)

This agreement (Agreement) is made by and between Horizon Orphan LLC, as successor in interest to Raptor Pharmaceuticals, Inc. (f/k/a Encode Pharmaceuticals, Inc.), a Delaware limited liability company having an address at 150 South Saunders Road, Lake Forest, Illinois 60045 (LICENSEE) and The Regents of the University of California, a California corporation having its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607-5200 (UNIVERSITY), represented by its San Diego campus having an address at University of California, San Diego, Office of Innovation and Commercialization, Mail Code 0910, 9500 Gilman Drive, La Jolla, California 92093-0910 (UCSD). This Agreement is being entered into as of the date of last signature below (Execution Date) and is deemed effective as of October 31, 2007 (Effective Date).

[***] CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. SECOND AMENDED AND RESTATED LICENSE AGREEMENT NO. 3 (Cora to Haemonetics; Current and Future IP Specific to TEG 6000 Apparatus) (August 7th, 2017)

This SECOND AMENDED AND RESTATED LICENSE AGREEMENT (including without limitation the schedules attached hereto, this "License Agreement") dated as of August 14, 2013 (the "Effective Date"), is entered into by and among: Cora Healthcare, Inc. (f/k/a Haemoscope Corporation), a Delaware corporation ("Cora Healthcare") and CoraMed Technologies, LLC, Delaware limited liability company ("CoraMed" and, collectively with Cora Healthcare, "Cora"), both having principal offices at 6225 West Howard Street, Niles, Illinois 60714; and Haemonetics Corporation, a Massachusetts corporation having its principal office at 400 Wood Road, Braintree, Massachusetts 02184-9144 ("Haemonetics").

Actinium Pharmaceuticals, Inc. – Amended and Restated License Agreement (August 4th, 2017)

This Agreement amends and restates in its entirety that certain Office Space License Agreement, dated as of March 10, 2016 and effective as of January 1, 2016, between Relmada and Actinium (the "Original Agreement") for office space within the Premises. This Agreement is intended to and does completely amend and restate the Original Agreement.